Inhibitors | Comment | Organism | Structure |
---|---|---|---|
1alpha,25-dihydroxyvitamin D3 | enzyme activity decreases by approximately 40% in the presence of the hormone | Homo sapiens | |
ZK191784 | enzyme activity decreases by approximately 25% in the presence of the hormone analogue | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | Q8TCT0 | - |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
SH-SY5Y cell | - |
Homo sapiens | - |
Synonyms | Comment | Organism |
---|---|---|
CERK | - |
Homo sapiens |
Organism | Comment | Expression |
---|---|---|
Homo sapiens | expression of the enzyme, after 24 h of treatment with 1alpha,25-dihydroxyvitamin D3 or its analogue ZK191784, is reduced by approximately 40 and 60%, respectively | down |
General Information | Comment | Organism |
---|---|---|
physiological function | ceramide kinase/ceramide 1-phosphate axis acts as molecular effector of the anti-proliferative action of 1alpha,25-dihydroxyvitamin D3 and its analogues. The inhibition of ceramide kinase by specific gene silencing or pharmacological inhibition, drastically reduces cell proliferation. 1alpha,25-Dihydroxyvitamin D3 and structural analogue ZK191784 treatment induce a significant decrease in ceramide kinase expression and ceramide 1-phosphate content, and an increase of ceramide. The treatment of SH-SY5Y cells with ZK159222, antagonist of 1alpha,25-dihydroxyvitamin D3 receptor, trichostatin A, inhibitor of histone deacetylases, and COUP-TFI-siRNA prevents the decrease of ceramide kinase expression elicited by 1alpha,25-dihydroxyvitamin D3 supporting the involvement of VDR/COUP-TFI/histone deacetylase complex in ceramide kinase regulation | Homo sapiens |